These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 22923696)

  • 1. Inhibitory signaling through signal regulatory protein-α is not sufficient to explain the antitumor activities of CD47 antibodies.
    Soto-Pantoja DR; Miller TW; Frazier WA; Roberts DD
    Proc Natl Acad Sci U S A; 2012 Oct; 109(42):E2842; author reply E2844-5. PubMed ID: 22923696
    [No Abstract]   [Full Text] [Related]  

  • 2. On the mechanism of CD47 targeting in cancer.
    Zhao XW; Matlung HL; Kuijpers TW; van den Berg TK
    Proc Natl Acad Sci U S A; 2012 Oct; 109(42):E2843; author reply E2844-5. PubMed ID: 22923695
    [No Abstract]   [Full Text] [Related]  

  • 3. The CD47-signal regulatory protein alpha (SIRPa) interaction is a therapeutic target for human solid tumors.
    Willingham SB; Volkmer JP; Gentles AJ; Sahoo D; Dalerba P; Mitra SS; Wang J; Contreras-Trujillo H; Martin R; Cohen JD; Lovelace P; Scheeren FA; Chao MP; Weiskopf K; Tang C; Volkmer AK; Naik TJ; Storm TA; Mosley AR; Edris B; Schmid SM; Sun CK; Chua MS; Murillo O; Rajendran P; Cha AC; Chin RK; Kim D; Adorno M; Raveh T; Tseng D; Jaiswal S; Enger PØ; Steinberg GK; Li G; So SK; Majeti R; Harsh GR; van de Rijn M; Teng NN; Sunwoo JB; Alizadeh AA; Clarke MF; Weissman IL
    Proc Natl Acad Sci U S A; 2012 Apr; 109(17):6662-7. PubMed ID: 22451913
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The CD47-SIRPα Immune Checkpoint.
    Logtenberg MEW; Scheeren FA; Schumacher TN
    Immunity; 2020 May; 52(5):742-752. PubMed ID: 32433947
    [TBL] [Abstract][Full Text] [Related]  

  • 5. SIRPα-CD47 Immune Checkpoint Blockade in Anticancer Therapy.
    Veillette A; Chen J
    Trends Immunol; 2018 Mar; 39(3):173-184. PubMed ID: 29336991
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Advances in Anti-Tumor Treatments Targeting the CD47/SIRPα Axis.
    Zhang W; Huang Q; Xiao W; Zhao Y; Pi J; Xu H; Zhao H; Xu J; Evans CE; Jin H
    Front Immunol; 2020; 11():18. PubMed ID: 32082311
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The CD47-SIRPα signaling axis as an innate immune checkpoint in cancer.
    Matlung HL; Szilagyi K; Barclay NA; van den Berg TK
    Immunol Rev; 2017 Mar; 276(1):145-164. PubMed ID: 28258703
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Targeting CD47 in Anaplastic Thyroid Carcinoma Enhances Tumor Phagocytosis by Macrophages and Is a Promising Therapeutic Strategy.
    Schürch CM; Roelli MA; Forster S; Wasmer MH; Brühl F; Maire RS; Di Pancrazio S; Ruepp MD; Giger R; Perren A; Schmitt AM; Krebs P; Charles RP; Dettmer MS
    Thyroid; 2019 Jul; 29(7):979-992. PubMed ID: 30938231
    [No Abstract]   [Full Text] [Related]  

  • 9. Functions and molecular mechanisms of the CD47-SIRPalpha signalling pathway.
    Matozaki T; Murata Y; Okazawa H; Ohnishi H
    Trends Cell Biol; 2009 Feb; 19(2):72-80. PubMed ID: 19144521
    [TBL] [Abstract][Full Text] [Related]  

  • 10. TSP1-CD47-SIRPα signaling facilitates the development of endometriosis by mediating the survival of ectopic endometrium.
    Liu Y; Li M; Wei C; Tang L; Sheng Y; Liu Y; Li D; Ding D; Qiu J; Zhu X
    Am J Reprod Immunol; 2020 Jun; 83(6):e13236. PubMed ID: 32196807
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dendritic Cells but Not Macrophages Sense Tumor Mitochondrial DNA for Cross-priming through Signal Regulatory Protein α Signaling.
    Xu MM; Pu Y; Han D; Shi Y; Cao X; Liang H; Chen X; Li XD; Deng L; Chen ZJ; Weichselbaum RR; Fu YX
    Immunity; 2017 Aug; 47(2):363-373.e5. PubMed ID: 28801234
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Disrupting the CD47-SIRPα anti-phagocytic axis by a humanized anti-CD47 antibody is an efficacious treatment for malignant pediatric brain tumors.
    Gholamin S; Mitra SS; Feroze AH; Liu J; Kahn SA; Zhang M; Esparza R; Richard C; Ramaswamy V; Remke M; Volkmer AK; Willingham S; Ponnuswami A; McCarty A; Lovelace P; Storm TA; Schubert S; Hutter G; Narayanan C; Chu P; Raabe EH; Harsh G; Taylor MD; Monje M; Cho YJ; Majeti R; Volkmer JP; Fisher PG; Grant G; Steinberg GK; Vogel H; Edwards M; Weissman IL; Cheshier SH
    Sci Transl Med; 2017 Mar; 9(381):. PubMed ID: 28298418
    [TBL] [Abstract][Full Text] [Related]  

  • 13. CD47 Blockade Inhibits Tumor Progression through Promoting Phagocytosis of Tumor Cells by M2 Polarized Macrophages in Endometrial Cancer.
    Gu S; Ni T; Wang J; Liu Y; Fan Q; Wang Y; Huang T; Chu Y; Sun X; Wang Y
    J Immunol Res; 2018; 2018():6156757. PubMed ID: 30525058
    [TBL] [Abstract][Full Text] [Related]  

  • 14. An antitumor peptide RS17-targeted CD47, design, synthesis, and antitumor activity.
    Wang X; Wang Y; Hu J; Xu H
    Cancer Med; 2021 Mar; 10(6):2125-2136. PubMed ID: 33629544
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Engineering macrophages to phagocytose cancer cells by blocking the CD47/SIRPɑ axis.
    Yang H; Shao R; Huang H; Wang X; Rong Z; Lin Y
    Cancer Med; 2019 Aug; 8(9):4245-4253. PubMed ID: 31183992
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Blockade of CD47 or SIRPα: a new cancer immunotherapy.
    Murata Y; Saito Y; Kotani T; Matozaki T
    Expert Opin Ther Targets; 2020 Oct; 24(10):945-951. PubMed ID: 32799682
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Targeting the myeloid checkpoint receptor SIRPα potentiates innate and adaptive immune responses to promote anti-tumor activity.
    Kuo TC; Chen A; Harrabi O; Sockolosky JT; Zhang A; Sangalang E; Doyle LV; Kauder SE; Fontaine D; Bollini S; Han B; Fu YX; Sim J; Pons J; Wan HI
    J Hematol Oncol; 2020 Nov; 13(1):160. PubMed ID: 33256806
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The potentiating effect of hTFPI in the presence of hCD47 reduces the cytotoxicity of human macrophages.
    Jung SH; Hwang JH; Kim SE; Young Kyu K; Park HC; Lee HT
    Xenotransplantation; 2017 May; 24(3):. PubMed ID: 28393401
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Development of Bispecific Antibody Derivatives for Cancer Immunotherapy.
    He Y; Helfrich W; Bremer E
    Methods Mol Biol; 2019; 1884():335-347. PubMed ID: 30465214
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Identification of Glutaminyl Cyclase isoenzyme isoQC as a regulator of SIRPα-CD47 axis.
    Wu Z; Weng L; Zhang T; Tian H; Fang L; Teng H; Zhang W; Gao J; Hao Y; Li Y; Zhou H; Wang P
    Cell Res; 2019 Jun; 29(6):502-505. PubMed ID: 31089204
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.